Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

global

- PMLiVE

Roche blasts UK’s ‘broken’ HTA system as Kadcyla rejected

But NICE says it is 'very disappointed' with the company's pricing policy

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

Research Partnership

- PMLiVE

SMC decides Celgene’s Imnovid is not cost-effective

Scottish cancer patients denied access to the cancer drug

EU flag

Updated EMA reports better suited to HTA needs

Changes to drug licensing reports are helping to support reimbursement decisions

- PMLiVE

Oxford PharmaGenesis launches its new HealthScience approach

Unveils integrated approach to engaging physicians, patients and policy-makers

- PMLiVE

Eisai resubmits Fycompa to G-BA for pricing assessment

But German distribution of epilepsy drug remains on hold until reimbursement settled

- PMLiVE

ABPI appoints value and access manager

Christine Rowland joins from Pfizer

- PMLiVE

NICE won’t back early use of Zytiga in prostate cancer

Says Janssen drug should not be used prior to chemotherapy

Oncology drugs under AMNOG: part one

Segmentation and comparator choice - lessons for cancer drug market access in Germany

UX: Designing Human Experiences

Applying science to the creative process to improve lives

Havas Lynx

National Institute for Health and Care Excellence NICE logo

NICE gives partial backing to Ferring’s prostate cancer drug

Firmagon on course for use on NHS in England and Wales

- PMLiVE

Interview: Georg Toufar, Mundipharma

Mundipharma’s chief marketing officer Georg Toufar on the benefits of having a smaller, more concentrated focus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links